Get all your news in one place.
100's of premium titles.
One app.
Start reading
StockNews.com
StockNews.com
Business
Subhasree Kar

Becton Dickinson & Co. (BDX) Earnings Moves: A Buy or Sell for Investors?

Becton, Dickinson and Company (BDX), a leading global med-tech organization, has made significant strides in cultivating ground-breaking technology, services, and solutions.

Owing to a robust portfolio and superior market positioning, the company looks positioned for stable growth in the about-to-be-reported quarter. However, declining COVID-related revenues will likely have impacted BDX’s Life Sciences segment’s revenues in the fiscal fourth quarter of 2023.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.